Clinical trials: B Cell
Philadelphia Positive Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult
Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
In recent years, immunotherapy (eg. blinatumomab, inotuzumab ozogamicin, CAR-T cells) has demonstrated a high safety and efficacy profile in relapsed/refractory (R/R）B-ALL.
- Trial name
- NCT06481228
- Testing
- CAR-T cells, Venetoclax, Olverembatinib
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Diffuse Large B Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Secondary Prognostic Index in RefrActory Lymphoma
60% of patients with diffuse large B cell lymphoma are healed after first-line treatment which whatever the age. For the remaining 40% of patients (relapses and primary refractories): 38% of patients will be cured with a 2nd line…
- Trial name
- SPiRAL (NCT04804865)
- Testing
- prognostic assessment
- Where
- 2 sites in France
- Volunteers
- 180 people
- Sponsor
- Weprom
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory
Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
SJCAR19 is a research study seeking to evaluate the use of chimeric antigen receptor (CAR) T cell therapy, a type of cellular therapy, for the treatment of pediatric, adolescent and young adult patients with relapsed or…
- Trial name
- NCT03573700
- Testing
- Cyclophosphamide, Fludarabine, Mesna
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- St. Jude Children's Research Hospital
Select Relapsed/Refractory Lymphoid Malignancies
A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1)
This is a multicenter, open-label, Phase 1 study of AUR104 in adult patients with select Relapsed/Refractory (R/R) Lymphoid Malignancies.
- Trial name
- VIJAY-1 (NCT06761586)
- Testing
- AUR104
- Where
- 5 sites in India
- Volunteers
- 9 people
- Sponsor
- Aurigene Discovery Technologies Limited
Chronic Lymphocytic Leukemia
A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)
The study is a Phase I, dose-escalating, non-randomized, single institution clinical trial assessing the safety and efficacy of autologous Ad-ISF35-transduced CLL B cells administered as a single intravenous infusion in patients…
- Trial name
- NCT00779883
- Testing
- ISF35
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Memgen, LLC
Leukemia, Lymphocytic, Chronic, B-Cell
Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients
This study involves adding the kinase inhibitor Ruxolitinib to Ibrutinib to treat Chronic Lymphocytic Leukemia (CLL).
- Trial name
- NCT02912754
- Testing
- ruxolitinib, ibrutinib
- Where
- 2 sites in Canada
- Volunteers
- 36 people
- Sponsor
- Sunnybrook Health Sciences Centre
Lymphoma, Waldenström Macroglobulinemia (WM)
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2003 in patients with different types of lymphoma
- Conditions
- Lymphoma, Waldenström Macroglobulinemia (WM), DLBCL - Diffuse Large B Cell Lymphoma, PMBCL
- Trial name
- NCT07249905
- Testing
- MDX2003
- Where
- 6 sites in Australia, Israel
- Volunteers
- 180 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma
A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL
This research study will be evaluating the safety and efficacy of a study drug called TGR-1202 in combination with a known drug ibrutinib, also known as Imbruvica, as a possible treatment for Chronic Lymphocytic Leukemia/Small…
- Trial name
- NCT02268851
- Testing
- TGR-1202, Ibrutinib
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- Dana-Farber Cancer Institute
Marginal Zone Lymphoma(MZL)
Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma
The goal of this clinical trial is to learn if Zanubrutinib, Rituximab, and Lenalidomide works to treat marginal zone lymphoma as the first-line therapy. It will also learn about the safety of the treatment.
- Trial name
- NCT07299331
- Testing
- Zanubrutinib, Rituximab, and Lenalidomide as first-line treatment for Marginal Zone Lymphoma, Zanubrutinib, Rituximab, and Lenalidomide as the primary treatment for Marginal Zone Lymphoma
- Volunteers
- 50 people
- Sponsor
- Zhengzhou University
Chronic Lymphocytic Leukemia (CLL)
Evaluation of the Immune Restoration Potential Of Lenalidomide
This is phase 2 study of the immunomodulatory drug, lenalidomide, to evaluate potential beneficial effects on the immune system of patients with chronic lymphocytic leukemia (CLL) and CLL-associated immunodeficiency.
- Trial name
- Revlimid (NCT02371577)
- Testing
- Lenalidomide
- Where
- United States
- Sponsor
- University of California, San Diego
Diffuse Large B-cell Lymphoma
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
In the current protocol version, there are two parts. Part I is a pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in…
- Trial name
- DALY 2-EU (NCT04844866)
- Testing
- MB-CART2019.1, Standard of Care
- Where
- 51 sites in Austria, Belgium and 12 more
- Volunteers
- 213 people
- Sponsor
- Miltenyi Biomedicine GmbH
Systemic Aspergillosis, Systemic Candidiasis
Antimycotic Prophylaxis in Pediatric Patients Following Allogeneic Stem Cell Transplantation
Pediatric patients are at high risk to acquire mycotic infections following allogeneic bone marrow transplantation. In the present retrospective analysis we assess the safety and efficacy of different regimens in antimycotic…
- Trial name
- NCT01040156
- Where
- Germany
- Sponsor
- University Children's Hospital Tuebingen
Lymphoma
Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma
RATIONALE: Antibiotics may stop the growth of Helicobacter pylori which may be associated with gastric lymphoma. PURPOSE: Phase II trial to study the effectiveness of antibiotic therapy in treating patients with low grade gastric…
- Trial name
- NCT00003151
- Testing
- bismuth subcitrate, amoxicillin, clarithromycin
- Where
- 22 sites in United Kingdom
- Volunteers
- 96 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Grade 3b Follicular Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
This phase I trial studies the side effects and best dose of vorinostat when given together with pembrolizumab in treating patients with diffuse large B-cell lymphoma, follicular lymphoma, or Hodgkin lymphoma that has come back…
- Conditions
- Grade 3b Follicular Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL, Recurrent Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
- Trial name
- NCT03150329
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab, Vorinostat
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- City of Hope Medical Center
B Cell Lymphoma, Follicular Lymphoma
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
The idiotype of the immunoglobulin on a given B cell malignancy (Id) can serve as a clonal marker, and a previous pilot study in lymphoma patients has demonstrated that autologous Id protein can be formulated into an immunogenic…
- Conditions
- B Cell Lymphoma, Follicular Lymphoma, Lymphoma
- Trial name
- NCT00001512
- Testing
- Id-KLH Vaccine, GM-CSF
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Hematologic Malignancy, Acute Leukemia
Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies
Prospective, multi-center open label study of HLA-partially to fully matched allogeneic cryopreserved deceased donor bone marrow transplantation and living donor transplantation for patients with hematologic malignancies.
- Conditions
- Hematologic Malignancy, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT07710781
- Testing
- Ossium HPC, Marrow, Standard of care living donor - Haplo Related, Standard of care living donor - Mismatched Unrelated
- Volunteers
- 300 people
- Sponsor
- Ossium Health, Inc.
Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
This is a phase I, interventional, single arm, open label, treatment study designed to evaluate the safety and efficacy of LV20.19 CAR -T cells with pirtobrutinib bridging and maintenance in adult patients with B cell…
- Conditions
- Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT05990465
- Testing
- Pirtobrutinib, LV20.19 CAR T cells
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Medical College of Wisconsin
Monkeypox
Prospective Study for the FOLLOW-UP of Human Monkeypox Cases and Smallpox Vaccinees at Risk
The goal of this observational study is to describe possible physical and psychological sequelae after an mpox infection and to evaluate the longevity of B- and T-cell immune responses in former mpox patients and vaccine…
- Trial name
- POQS-FU PLUS (NCT05879965)
- Where
- Belgium
- Volunteers
- 345 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements
Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma
This phase II trial studies how well polatuzumab vedotin and combination chemotherapy work in treating patients with previously untreated double, triple hit lymphoma, Double Expressor Lymphoma or High-Grade B Cell Lymphoma.
- Conditions
- Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6 Rearrangements, Double Expressor Lymphoma
- Trial name
- NCT04479267
- Testing
- Prednisone, Prednisolone, Methylprednisolone
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Large B-cell Lymphoma
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have…
- Trial name
- ALPHA3 (NCT06500273)
- Testing
- cemacabtagene ansegedleucel, Fludarabine, Cyclophosphamide
- Where
- 86 sites in United States, Australia and 2 more
- Volunteers
- 250 people
- Sponsor
- Allogene Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.